Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Bactiguard Holding AB (publ)
  6. News
  7. Summary
    BACTI B   SE0005878741


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Bactiguard : Extended Malaysian wound care tender

08/25/2021 | 02:36am EDT

Bactiguard's tender award for wound care products for the public sector in Malaysiahas been extended by another year and the volume has increased. This enables healthcare providers in both primary and secondary care to purchase Bactiguard's Wound Care system for infection prevention.

"The public sector in Malaysia has consumed almost half a million bottles of our wound care products during the past five years with very positive outcome. Therefore, the Ministry of Health has extended the contract by another year with and increased the volume by 20 precent, which clearly shows that it adds value for patients and clinicians", says Peter Rådqvist, Global Head of Sales at Bactiguard.

"My experience with the Bactiguard wound care solution has been very good. At the University Medical Center (UKM) in Kuala Lumpur, we have used the solution for intra operative irrigation of open fractures and as a disinfectant for infected wounds and joints, as well as part of our general wound management practice", states Dr Badrul Akmal Hisham<s>,</s> Consultant Orthopedic and Arthroscopy & Sports Surgeon at UKM Medical Center, Kuala Lumpur.

"I strongly recommend Bactiguard's Wound Care solution as the ultimate antiseptic, as it is non-toxic to human cells and at the same time very effective as a bactericidal, virucidal, fungicidal and sporicidal", Dr Badrul Akmal Hisham concludes.

About Bactiguard Wound Care

Bactiguard Wound Care is a biocompatible, pH-neutral and water-based product line that supports the natural wound healing and cleans the wound by reducing the microbial load. The products can be used for both acute and chronical wounds.

Bactiguard Wound Care contains hypochlorous acid, the same substance as the body's immune cells use in their defence against infectious organisms. The products neither smell strongly or sting, but effectively kills most viruses, bacteria and fungi that cause infections. They have no negative effect on human cells, which means that they are not irritating to the body.

Read more about Bactiguard Wound Care >>>

For further information, please contact:
Petra Kaur, Chief Marketing and Communication Officer, mobile +46 79 304 96 36

About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with Bactiguard's coating are market leaders in the USA and Japan through our licensing partner BD. Bactiguard's product portfolio also includes a non-alcoholic product line for wound care and disinfection. It effectively kills viruses, bacteria and fungi while being biocompatible, pH neutral and tissue friendly. The active ingredient hypochlorous acid is the same substance as the body's immune cells use in their defence against infectious organisms.

Bactiguard is in a strong expansion phase in the markets in Europe, China, India and the Middle East through our own product portfolio and by establishing licensing deals in new therapy areas. Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about Bactiguard www.bactiguard.com




(c) 2021 Cision. All rights reserved., source Press Releases - English

10/08BACTIGUARD : More than 50% risk reduction of ventilator associated pneumonia with Bactigua..
10/05BACTIGUARD : New clinical trial shows 53% reduction of ventilator-associated pneumonia wit..
10/05BACTIGUARD : New clinical trial shows 53% reduction of ventilator-associated pneumonia wit..
10/05New Clinical Trial Shows 53% Reduction of Ventilator-Associated Pneumonia with Bactigua..
09/30BACTIGUARD : Increased number of shares and votes in Bactiguard
09/27BACTIGUARD : Impact of COVID-19 on healthcare associated infections
09/21BACTIGUARD : completes a directed new share issue to AMF, raising approximately SEK 228 mi..
09/21Bactiguard Holding AB announced that it has received SEK 228 million in funding from AM..
09/14BACTIGUARD : Aniocyn, now available in stores in the Nordic region
09/11BACTIGUARD : Sepsis always starts with an infection – causes at least 11 M deaths gl..
More news
Sales 2020 177 M 20,5 M 20,5 M
Net income 2020 -38,4 M -4,45 M -4,45 M
Net Debt 2020 254 M 29,4 M 29,4 M
P/E ratio 2020 -125x
Yield 2020 -
Capitalization 5 432 M 627 M 629 M
EV / Sales 2019 15,5x
EV / Sales 2020 28,6x
Nbr of Employees -
Free-Float 38,0%
Duration : Period :
Bactiguard Holding AB (publ) Technical Analysis Chart | BACTI B | SE0005878741 | MarketScreener
Technical analysis trends BACTIGUARD HOLDING AB (PUBL)
Short TermMid-TermLong Term
Income Statement Evolution
Managers and Directors
Anders G÷ransson Chief Executive Officer
Gabriella Bj÷rknert Caracciolo Chief Financial Officer & Deputy CEO
Nils Thomas von Koch Chairman
Stefan Grass Chief Medical Officer & Deputy CEO
Sathish Subramaniam Chief Operations Officer